

# BIOTECH INVESTING: IS THERE A DOCTOR IN THE HOUSE?

Rudi Van den Eynde,

Head of Thematic Global Equity and fund manager of Candriam Equities L Biotechnology at Candriam, answers investors' questions about a sector where depth of specialist knowledge is a prerequisite to consistent stock selection success.



## What are the key drivers to the performance of the biotech sector?

Of all the sectors praised to the heavens at the time of the dot-com bubble, the only firms to have truly lasted the course are biotechnology companies. There are good reasons for this.

In 2013, six of the ten best selling drugs worldwide were biotechnology drugs, including the No. 1 seller, anti-inflammatory Humira. Pricing power among biotech firms also remains strong. The sector as a whole is also less vulnerable to generic competition due to its inherent scientific complexity and due to the necessity of holding costly clinical trials. Corporate activity is an omnipresent factor too as cash-rich companies bolt on smaller biotechs to boost overall growth rates.

But what usually escapes most investors who are not experienced biotech specialists is that the major driver to performance in the sector is medical innovation.

## What does this mean for investors?

Improved scientific instruments and a better understanding of the underlying causes of diseases are leading to big improvements in drug efficacy and innovation. These are the major drivers of individual share price performance.

For investors, these characteristics result for example in a relatively low correlation between the performance of the biotech sector and the wider equity market. The vagaries of the broader economic cycle are, after all, largely irrelevant in the success or failure of drug development founded on many years of hard work in the laboratory.

And while there is certainly competition in some treatment areas, individual companies very rarely have exposures to precisely the same risk factors. Biotech is therefore very much a stockpickers' universe. But it is also one which requires huge specialist knowledge.

## When is the right stage of drug development to invest in biotechs?


In the early stages, investment can certainly yield very high profits. However, these returns inevitably go hand in hand with a great deal of risk. At the other end of drug development, you are likely to miss the vast majority of the profit potential if you wait until all of the clinical development phases have been completed successfully.

However, we believe that there is a "sweet spot" in the risk/reward trade-off that lies between these two extremes. This is after "Phase II" of a drug's development has been successfully concluded.



## CANDRIAM HEALTHCARE TEAM

“Interpreting the data requires a deep understanding of the disease settings”



### What does successful stock picking in the biotechnology sector involve?

In-depth clinical assessments, much less the valuation models, are the critical factor in determining biotech company investment returns. Medical drugs are developed by doctors, approved by doctors at the regulatory bodies and they are prescribed by doctors.

Thinking like a doctor and understanding the needs and processes followed by the medical profession are therefore the key elements to consistent alpha generation. But this is a scientifically complex world which requires experience and a depth of specialist knowledge that cannot be quickly or easily assimilated.

### What differentiates Candriam in mastering the inherent scientific complexity of this sector?

Since inception, Candriam’s biotech

strategy has been managed by the same fund manager, and has always benefited from this dependable mix of knowledge and experience these past 14 years. Contrary to intuition the outcomes of clinical trials are not always binary, not always black or white. Interpreting the data requires a deep understanding of the disease settings and over the years we have been able to thoroughly develop this, with the healthcare team expanded to 4 people including two dedicated biotechnology analysts.

### Does the strong performance of biotechs over the last few years mean the sector is now overvalued?

Many observers are now questioning whether the sector can maintain its recent strong performance. But when analysing early-stage biotech companies most financial analysis should be put to one side.

Despite the recent bullish performance

we still take a positive view of the sector’s future. In particular we view medical innovation as something that will continue in the long term, with pricing for new drugs remaining strong. Innovation never sleeps, and progress is evident in many fields: research in oncology, auto-immune or orphan diseases.

Against this backdrop and in the context of many biotech companies’ potential growth, valuations for the sector do not look unreasonable. As always, biotech remains an opportunity-rich universe for skilled stock pickers.

FIND OUT MORE ABOUT  
OUR FUNDS AND  
THEIR RISK PROFILES:



[www.mastering-fortomorrow.com](http://www.mastering-fortomorrow.com)

## INVESTING FOR TOMORROW

Important information: For European Professional Investors only.

This document is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval. Candriam consistently recommends investors to consult via our website [www.candriam.com](http://www.candriam.com) the key information document, prospectus, and all other relevant information prior to investing in one of our funds. These documents are available either in English or in local languages for each country where the fund’s marketing is approved. The funds mentioned may not be available for public distribution in all jurisdictions. All or some of the Candriam Equities L Biotechnology share classes are only registered for public distribution in Austria, Belgium, Switzerland, Germany, Spain, Finland, France, Italy, Luxembourg, The Netherlands, Portugal, Sweden and United Kingdom. The representative and the paying agent for the funds in Switzerland are RBC Investor Services Bank S.A., Esch-sur-Alzette, Succursale de Zurich, Badenerstrasse 567, CH-8048 Zurich.

**CANDRIAM**  
INVESTORS GROUP   
A NEW YORK LIFE COMPANY